Previous 10 | Next 10 |
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment; Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings Potentially Translatable to Multiple T Cell-Mediated Autoimmune Diseases CAMBRIDGE, Mass....
Rubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. They have some cash, but it may not last them long enough. For further details see: Rubius: Poor Data, Punishing Environment, Beaten Stock
Gainers: Heart Core Enterprises (HTCR) +151%. MINISO Group Holding (MNSO) +33%. Imperial Petroleum (IMPP) +33%. Cyren (CYRN) +33%. One Connect Financial Technology (OCFT) +27%. SQL Technologies (SKYX) +27%. Rekor Systems (REKR) +27%. Rubius Therapeutics (RUBY) +24%. Bluejay Diagnostics (BJDX)...
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment...
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...
Rubius Therapeutics (NASDAQ:RUBY) is trading lower into afternoon trading on Wednesday after H.C. Wainwright lowered the price target for clinical-stage biotech citing an update on the company’s Phase 1 trial for the cell therapy candidate, RTX-240 in advanced solid tumors. Announcing ...
News, Short Squeeze, Breakout and More Instantly...
Rubius Therapeutics Inc. Company Name:
RUBY Stock Symbol:
OTCMKTS Market:
Rubius Therapeutics Inc. Website:
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...